## **NSQIP** Impacts Patient Experience

Maria Castaldi, MD, FACS<sup>1,2</sup>, Geena George, MPH<sup>2</sup>, Pamela Turner, MSN, RN<sup>1</sup>, and John McNelis, MD, FACS<sup>1</sup>

Journal of Patient Experience 2020, Vol. 7(1) 89-95 © The Author(s) 2018 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/2374373518817081 journals.sagepub.com/home/jpx



#### **Abstract**

National Quality Improvement Project (NSQIP) semiannual reports (SARs) revealed high observed to expected ratios for venous thromboembolic events (VTEs) on the surgical service. Press Ganey scores identified an area of particular weakness in shared decision-making in patient care. Patients reported little to no participation in shared decision-making. A performance improvement project was developed with a 2-fold objective: decrease the percentages of patients sustaining VTE through adequate screening and prophylaxis (VTEP) and to engage patients in shared decision-making to accept VTEP through enhanced patient-centered discussions and education on the risks and benefits of VTEP. A clinical pathway was developed to implement VTEP using a standardized risk assessment tool. Patient-centered discussion introduced VTEP and impact on perioperative safety. Results included telephone survey, NSQIP SARs, and Press Ganey patient experience survey. Using NSQIP data and a pathway developed for both VTE risk assessment and patient engagement, the authors observe immediate improvements in patient experience and decreased rates of VTE.

### **Keywords**

communication, outpatient satisfaction data, patient engagement, patient safety, physician engagement, quality improvement, team communication

## Introduction

Venous thromboembolism (VTE) can be comprised of a deep vein thrombosis (DVT) and/or a pulmonary embolism. It is estimated that approximately 900 000 people are affected by VTE annually in the United States (1), with hospitalized patients forming the majority of affected individuals as they experience a 100-fold incidence of VTE when compared with the general population (2). Furthermore, VTE can be found in approximately 80% of surgical patients who were not placed on thromboprophylaxis (3). Although several reports from randomized controlled trials have demonstrated the effectiveness and safety of thromboprophylaxis in the prevention of VTE (4), several studies have shown that these interventions are underutilized in hospitals (5,6). The increased morbidity and mortality associated with VTE highlights the great importance of treating and preventing VTE.

In May 2013, Jacobi Medical Center joined the American College of Surgeons National Quality Improvement Project (NSQIP) (7). The NSQIP measures and tracks risk-adjusted surgical outcomes and gives unbiased comparisons of results between hospitals. Data from NSQIP indicated that our facility had a higher than expected incidence of venous thromboembolic events, with multiple surgical subspecialty services needing significant improvement (Figure 1).

Concurrently, our corporation added Press Ganey scores to the hospital scorecard performance indicators. These scores demonstrated that one area of particular weakness was in shared decision-making in patient care.

A recent study aimed at understanding patient perceptions of VTE prevention found that patients typically had poor understanding about VTE, the severity of postop VTE, and VTE prevention (8). Kahn et al in a recent review which examined system-wide interventions that contributed to the implementation of VTE in surgical patients reported that the alerts were associated with more patients receiving prophylaxis (4). Their findings emphasized the importance of both patient understanding and patient compliance in appropriately addressing these problems.

Our objective was 2-fold: first to decrease the percentages of patients sustaining VTE through adequate screening and prophylaxis (VTEP) and second to engage patients in shared


#### **Corresponding Author:**

Maria Castaldi, Department of Surgery, Westchester Medical Center, 100 Woods Road, Taylor Pavilion D344, Valhalla, NY 10595, USA. Email: maria.castaldi@wmchealth.org



<sup>&</sup>lt;sup>1</sup> Jacobi Medical Center, Bronx, NY, USA

Westchester Medical Center, Valhalla, NY, USA



**Figure 1.** (A) Baseline NSQIP O:E, division of general surgery. (B) Baseline NSQIP O:E, all surgical divisions.

decision-making to accept VTEP through enhanced patientcentered discussions and education on the risks and benefits of VTEP. It was hypothesized by the authors that this shared decision-making would lead to improved patient experience.

## **Methods**

## Formation of VTEP Protocol

Prior to data collection, a Quality Improvement (QI) program was created. Given that corrective action for implementation of VTEP program would cross multiple disciplines, a comprehensive steering committee was formed. Representatives of the departments of Surgery, Perioperative Nursing, and Anesthesia convened and performed a gap analysis. The group reviewed the literature regarding VTEP and evaluated existing risk assessment tools. The General Surgery service was selected for the study. The Caprini VTE Risk Factor Assessment Tool (9) was chosen to assess patient risk for VTE and a process was developed for risk assessment and administration of VTEP. During monthly Operating Room (OR) committee meetings, education was provided to the members of the departments of surgery, anesthesia, and nursing on Caprini risk assessment, VTEP, and patient-centered

discussions. Special attention was paid to the frontline surgical physician assistants (PAs), who would be responsible for ordering VTEP.

### Patient Selection and Assessment

This was a prospective interventional study of all patients undergoing surgery in the general surgery division between November 2016 and October 2017. All patients undergoing general surgery procedures at our institution were identified as potential candidates for VTEP and score for VTE risk preoperatively. Exclusion criteria are patients from nongeneral surgery service specialties (neurosurgery, ophthalmology, otolaryngology) and patients with contraindications for administration of VTEP: active bleeding, ingestion of oral anticoagulants, administration of glycoprotein IIb/IIIa inhibitors, and history of heparin-induced thrombocytopenia. Although some cases were day cases, not all with bleeding risks, the final decision to give VTEP was ultimately determined by the attending surgeon based on risk of VTE versus risk of postoperative bleeding. The risk of VTE far outweighed the risk of postoperative bleeding and no surgeon refused to give VTEP for high-risk patients. Using the Caprini score scale (Figure 2), a risk factor score was generated by nursing during the preoperative assessment. The score was recalculated the day of surgery by surgical PA staff trained in VTEP. Patients with total risk factor scores ≥3, reflecting moderate- to high-risk levels, indicating a 20% to 40% incidence of DVT, were identified. An alert was attached to the patient's chart to indicate a moderateto high-risk patient requiring VTEP.

# Pre- and Postoperative Patient Discussion and Interventions

The VTE alerts in turn prompted 2 separate discussions between surgeon, nurse, and patient regarding safety and VTEP. The initial discussion was done by phone by perioperative nurses during preadmission evaluation. The second discussion takes place face-to-face with the patient on the day of surgery in the holding area by both the surgeon and anesthesiologist. The patients were asked to describe their knowledge of blood clots. The risks and benefits of VTEP were explained to the patient after which patient comprehension was evaluated. The surgeon was then informed of risk assessment for final approval, and if warranted, preoperative VTEP was administered at recommended doses in the same day surgery holding unit. To facilitate discussion and to limit variation in message to patient, a scripted dialogue was developed for both assessment and follow-up with focus on patient-centered discussion (Figure 3). Telephone surveys were conducted 3 to 5 days postoperatively to assess patient understanding, perception, and experience. Outcomes measures included DVT, VTE, and patient experience with special attention to shared decision-making. Methods are summarized in Figure 4.

Castaldi et al 91

	HEALTH+ HOSPITALS	Jacobi			
De	ep Vein Th	rombosis (DVT)	BIRTHDATE		
	Prophyla	axis Orders	NAME		
(For use	in Elective G	General Surgery Patients)	10000		
Thrombo	sis Risk F	actor Assessment	CPI No.		
(0	hoose all	that apply)	SEX M F VISIT No.		
Each R		presents 1 Point	Each Risk Factor R	epresents 2 Points	5
☐ Age 41-60 years ☐ Swollen legs (curre ☐ Varicose veins	ent) Conge	myocardial infarction stive heart failure (<1 month) al patient currently at bed rest	☐ Arthroscopic surgery ☐ Malignancy (present or previo		
Obesity (BMI >25) Minor surgery plan Sepsis (<1 month)	ned  History  Abnorr	y of inflammatory bowel disease y of prior major surgery (<1 month) mal pulmonary function (COPD)	☐ Immobilizing plaster cast (<1 :	nours) month)	
☐ Serious Lung disea ☐ Oral contraceptives ☐ Pregnancy or posts	s or hormone reportum (<1 mont	placement therapy (h)	☐ History of DVT/PE ☐	Family History of the Positive Prothrombin	ombosi 20210A
abortion (≥ 3), premat		nt, recurrent spontaneous kemia or growth-restricted infant	☐ Positive Factor V Leiden ☐ I		agulant
□ Other risk factors_		Subtotal:	Heparin-induced thrombocyto     (Do not use heparin or any love)	penia (HIT)	narin)
Fach D	ek Factor Per	presents 5 Points	☐ Elevated anticardiolipin antibo	odies	Subtotal
Stroke (<1 month)		Multiple trauma (<1 month)	Other congenital or acquired t  If yes: Type	тотпортша	uptota
7 Flactive medicateve	er extremity arthr	roplasty	* most frequently missed risk f	actor	
	acture (<1 month	Subtotal:	most requently missed risk i		
☐ Hip, pelvis or leg fr.☐ Acute spinal cord in	Patient may of Oral Anticoagu	FACTORS ASSOCIATED WIT y not be a candidate for anticoagu ulants, Administration of glycoprotein SIDERATIONS FOR THE USE OF:	TOTAL RISK FACTOR HINCREASED BLEEDING ant therapy & SCDs should be consi IIb/IIIa inhibitors, History of heparin ind HEQUENTIAL COMPRESSION DEVICE	dered. uced thrombocytopenia	1
Hip, pelvis or leg fr. Acute spinal cord in Active Bleed, Ingestion	Patient may of Oral Anticoagu GLINICAL GON atient may not b	FACTORS ASSOCIATED WIT  I not be a candidate for anticoagu  Jlants, Administration of glycoprotein  SIDERATIONS FOR THE USE OF  a candidate for SCDs & alternati	TOTAL RISK FACTOR  H INCREASED BLEEDING ant therapy & SCDs should be consi IIb/Illa inhibitors, History of heparin ind 3EQUENTIAL COMPRESSION DEVICE ve prophylactic measures should be Disease, CHF, Acute Superficial DVT	dered. uced thrombocytopenia	7
Hip, pelvis or leg fr. Acute spinal cord in Active Bleed, Ingestion  Total Risk Factor Score	Patient may of Oral Anticoagu GUNICAL GON atient may not b Pati	FACTORS ASSOCIATED WIT  I not be a candidate for anticoagu  Jlants, Administration of glycoprotein  SIDERATIONS FOR THE USE OF  e a candidate for SCDs & alternati  ents with Severe Peripheral Arterial	TOTAL RISK FACTOR HINCREASED BLEEDING ant therapy & SCDs should be consi Ilb/Illa inhibitors, History of heparin ind HEQUENTIAL COMPRESSION DEVICE ve prophylactic measures should be	dered. uced thrombocytopenia	
Hip, pelvis or leg fr. Acute spinal cord in Active Bleed, Ingestion	Patient may of Oral Anticoage GEINICAL GON atlent may not b	FACTORS ASSOCIATED WIT  I not be a candidate for anticoagu  Jlants, Administration of glycoprotein  SIDERATIONS FOR THE USE OF  a candidate for SCDs & alternati	TOTAL RISK FACTOR  HINCREASED BLEEDING ant therapy & SCDs should be consi IIb/Illa inhibitors, History of heparin ind SEQUENTIAL COMPRESSION DEVICE ve prophylactic measures should be Disease, CHF, Acute Superficial DVT  Prophylaxis Regimen	dered. uced thrombocytopenia	3
Active Bleed, Ingestion  Total Risk Factor Score  0 1-2	Patient may of Oral Anticoage GENICAL GON attent may not b Pati Risk Level VERY LOW LOW	FACTORS ASSOCIATED WIT not be a candidate for anticoagulants, Administration of glycoprotein SIDERATIONS FOR THE USE OF a candidate for SCDs & alternatients with Severe Peripheral Arterial Early ambulation  Sequential Compression Dev Choose ONE of the following in Sequential Compression Deu Heparin 5000 units SQ TID	TOTAL RISK FACTOR  HINCREASED BLEEDING ant therapy & SCDs should be consi IIIb/IIIa inhibitors, History of heparin ind SEQUENTIAL COMPRESSION DEVICE ve prophylactic measures should be Disease, CHF, Acute Superficial DVT  Prophylaxis Regimen  ce (SCD) edications +/- compression devices: vice (SCD) - Optional	dered. uced thrombocytopenia 38 (SGD) considered.	3
Active Bleed, Ingestion  Total Risk Factor Score  0	Patient may of Oral Anticoagu GEINICAL CON atient may not b Pati Risk Level VERY LOW	FACTORS ASSOCIATED WIT on the a candidate for anticagulants, Administration of glycoprotein SIDERATIONS FOR THE USE OF e a candidate for SCDs & alternatients with Severe Peripheral Arterial Early ambulation  Sequential Compression Devices of the following in Sequential Compression Devices on the parin 5000 units SQ TID  Enoxaparin/Lovenox: 040	TOTAL RISK FACTOR  HINCREASED BLEEDING ant therapy & SCDs should be consi IIIb/IIIa inhibitors, History of heparin ind BEQUIENTIAL GOMPRESSION DEVICE ve prophylactic measures should be Disease, CHF, Acute Superficial DVT  Prophylaxis Regimen  ce (SCD) nedications +/- compression devices: vice (SCD) - Optional  mg SQ daily (WT < 150kg, CrCl > 30 mg SQ daily (WT < 150kg, CrCl = 10- mg SQ BID (WT > 150kg, CrCl > 30m g SQ BID (WT > 150kg, CrCl > 30m	dered. uced thrombocytopenia SS(SCD) considered.  mL/min) -29mL/min)	3
Total Risk Factor Score  0 1-2 3-4	Patient may of Oral Anticoage GEINICAL GON atlent may not b Pati Risk Level VERY LOW LOW MODERATE	FACTORS ASSOCIATED WIT not be a candidate for anticoagu ulants, Administration of glycoprotein SIDERATIONS FOR THE USE of a candidate for SCDs & alternatients with Severe Peripheral Arterial ents with Severe Peripheral Arterial Sequential Compression Devictoose QNE of the following in Sequential Compression Devictoose QNE of the following in Sequential Compression Devictoose QNE of the following in Sequential Compression Devictors SQ TID Sequ	TOTAL RISK FACTOR  HINCREASED BLEEDING ant therapy & SCDs should be consi IIIb/IIIa inhibitors, History of heparin ind GEQUENTIAL GOMPRESSION DEVICE ve prophylactic measures should be Disease, CHF, Acute Superficial DVT  Prophylaxis Regimen  ce (SCD) nedications +/- compression devices: vice (SCD) - Optional mg SQ daily (WT < 150kg, CrCl > 30 mg SQ daily (WT < 150kg, CrCl > 30 mg SQ BID (WT > 150kg, CrCl > 30 mines on the back of this form) inedications PLUs compression devices (Vice (SCD) (Preferred with Epidurals)	dered. uced thrombocytopenia S(SCD) considered.  mL/min) -29mL/min) nL/min) es:	
Active Bleed, Ingestion  Total Risk Factor Score  0 1-2	Patient may of Oral Anticoage GENICAL GON attent may not b Pati Risk Level VERY LOW LOW	FACTORS ASSOCIATED WIT on the a candidate for anticagual ants, Administration of glycoprotein SIDERATIONS FOR THE USE OF ea candidate for SCDs & alternatients with Severe Peripheral Arterial eints with Severe Peripheral Arterial Sequential Compression De Choose ONE of the following in Sequential Compression De Heparin 5000 units SQ TID Choose ONE of the following in Sequential Compression De Sequential Compression De Heparin 5000 units SQ TID Enoxaparin/Lovenox (Preference of the following in Sequential Compression De Heparin 5000 units SQ TID Enoxaparin/Lovenox (Preference of the following in Sequential Compression De Heparin 5000 units SQ TID Enoxaparin/Lovenox (Preference of the following in Sequential Compression De Heparin 5000 units SQ TID	TOTAL RISK FACTOR  HINCREASED BLEEDING ant therapy & SCDs should be consi Ilb/Illa inhibitors, History of heparin ind 3EQUENTIAL COMPRESSION DEVICE ve prophylactic measures should be Disease, CHF, Acute Superficial DVT  Prophylaxis Regimen  Ce (SCD) nedications +/- compression devices: vice (SCD) - Optional  mg SQ daily (WT < 150kg, CrCl > 30 mg SQ daily (WT < 150kg, CrCl > 30 mg SQ BID (WT > 150kg, CrCl > 30 mines on the back of this form) nedications PLUS compression device vice (SCD) Preferred with Epidurals) red): □ 40mg SQ daily (WT < 150kg, □ 30mg SQ daily (WT < 150kg, □ 30mg SQ daily (WT > 150kg, □ 30mg SQ daily (WT > 150kg, □ 30mg SQ daily (WT > 150kg, □ 30mg SQ BID (WT > 150kg, □ 30mg SQ BID (WT > 150kg, □ 30mg SQ BID (WT > 150kg,	dered. uced thrombocytopenia 33 (SCD) considered.  mL/min) -29mL/min) aL/min) es: , CrCl > 30mL/min) , CrCl = 10-29mL/min)	
Hip, pelvis or leg from Acute spinal cord in Acute spinal cord in Active Bleed, Ingestion  Total Risk Factor Score 0 1-2 3-4	Patient may of Oral Anticoage GEINICAL GON atlent may not b Pati Risk Level VERY LOW LOW MODERATE	FACTORS ASSOCIATED WIT on the a candidate for anticagual ants, Administration of glycoprotein SIDERATIONS FOR THE USE OF ea candidate for SCDs & alternatients with Severe Peripheral Arterial eints with Severe Peripheral Arterial Sequential Compression De Choose ONE of the following in Sequential Compression De Heparin 5000 units SQ TID Choose ONE of the following in Sequential Compression De Sequential Compression De Heparin 5000 units SQ TID Enoxaparin/Lovenox (Preference of the following in Sequential Compression De Heparin 5000 units SQ TID Enoxaparin/Lovenox (Preference of the following in Sequential Compression De Heparin 5000 units SQ TID Enoxaparin/Lovenox (Preference of the following in Sequential Compression De Heparin 5000 units SQ TID	TOTAL RISK FACTOR  HINCREASED BLEEDING ant therapy & SCDs should be consi Ilb/Illa inhibitors, History of heparin ind IEQUENTIAL COMPRESSION DEVICE ve prophylactic measures should be Disease, CHF, Acute Superficial DVT  Prophylaxis Regimen  Ce (SCD)  redications +/- compression devices: vice (SCD) - Optional  mg SQ daily (WT < 150kg, CrCl > 30 mg SQ daily (WT < 150kg, CrCl > 30 mg SQ BID (WT > 150kg, CrCl > 30 mines on the back of this form) redications PLUS compression device vice (SCD)  red): J 40mg SQ daily (WT < 150kg  J 30mg SQ daily (WT < 150kg)  J 30mg SQ daily (WT < 150kg)	dered. uced thrombocytopenia 33 (SCD) considered.  mL/min) -29mL/min) aL/min) es: , CrCl > 30mL/min) , CrCl = 10-29mL/min)	
Hip, pelvis or leg from Acute spinal cord in Acute spinal cord in Acute spinal cord in Acute Bleed, Ingestion  Total Risk Factor Score 0 1-2 3-4 5 or more	Patient may of Oral Anticoage GEINICAL CON atient may not be Patient m	FACTORS ASSOCIATED WIT on the a candidate for anticoagulants, Administration of glycoprotein SIDERATIONS FOR THE USE OF a candidate for SCDs & alternaticints with Severe Peripheral Arterial Early ambulation  Bequential Compression Deviction of the following in Sequential Compression Deviction of	TOTAL RISK FACTOR  HINCREASED BLEEDING ant therapy & SCDs should be consi IIb/IIIa inhibitors, History of heparin ind SEQUENTIAL COMPRESSION DEVICE vo prophylactic measures should be Disease, CHF, Acute Superficial DVT  Prophylaxis Regimen  Ce (SCD)  redications +/- compression devices: vice (SCD) - Optional  mg SQ daily (WT < 150kg, CrCl > 30 mg SQ daily (WT < 150kg, CrCl > 30 mg SQ BID (WT > 150kg, CrCl > 30 mines on the back of this form) redications PLUS compression device (SCD)  Preferred with Epidurals) red): □ 40mg SQ daily (WT < 150kg, □ 30mg SQ BID (WT > 150kg, □ 30mg SQ BID (WT > 150kg, suidelines on the back of this form)	dered. uced thrombocytopenia 33 (SCD) considered.  mL/min) -29mL/min) aL/min) es: , CrCl > 30mL/min) , CrCl = 10-29mL/min)	) S. FACS. R'
Hip, pelvis or leg from Acute spinal cord in Acute spinal cord in Acute Bleed, Ingestion  Total Risk Factor Score 0 1-2 3-4 5 or more	Patient may of Oral Anticoage GEINICAL CON atient may not be Patient m	FACTORS ASSOCIATED WIT on the a candidate for anticoagulants, Administration of glycoprotein SIDERATIONS FOR THE USE OF a candidate for SCDs & alternaticints with Severe Peripheral Arterial Early ambulation  Bequential Compression Deviction of the following in Sequential Compression Deviction of	TOTAL RISK FACTOR  HINCREASED BLEEDING ant therapy & SCDs should be consi IIIb/IIIa inhibitors, History of heparin ind SEQUENTIAL COMPRESSION DEVICE ve prophylactic measures should be Disease, CHF, Acute Superficial DVT  Prophylaxis Regimen  Ce (SCD) nedications +/- compression devices: vice (SCD) - Optional mg SQ daily (WT < 150kg, CrCl > 30 mg SQ daily (WT < 150kg, CrCl > 30 mg SQ daily (WT < 150kg, CrCl > 30 mines on the back of this form) nedications PLUS compression device (SCD)  Preferred with Epidurals) red): □ 40mg SQ daily (WT < 150kg □ 30mg SQ daily (WT < 150kg, uddelines on the back of this form)	dered.  uced thrombocytopenia 35 (SCD) considered.  mL/min) -29mL/min) sL/min)  ps: , CrCl > 30mL/min) , CrCl = 10-29mL/min CrCl > 30mL/min)	) is, FACS, Ri nent Tool
Hip, pelvis or leg from Acute spinal cord in Acute spinal cord in Acute spinal cord in Acute Bleed, Ingestion  Total Risk Factor Score 0 1-2 3-4 5 or more	Patient may of Oral Anticoage GEINICAL CON atient may not be Patient m	FACTORS ASSOCIATED WIT on the a candidate for anticoagulants, Administration of glycoprotein SIDERATIONS FOR THE USE OF a candidate for SCDs & alternatients with Severe Peripheral Arterial eints with Severe Peripheral Arterial Sequential Compression Deviction Choose ONE of the following in Sequential Compression Deviction Sequential Compression Deviction Choose ONE of the following in Sequential Compression Deviction Sequential Compression Deviction Choose ONE of the following in Sequential Compression Deviction Sequential Compression Sequential Compression Deviction Sequential Compressi	TOTAL RISK FACTOR  HINCREASED BLEEDING ant therapy & SCDs should be consi IIIb/IIIa inhibitors, History of heparin ind SEQUENTIAL COMPRESSION DEVICE ve prophylactic measures should be Disease, CHF, Acute Superficial DVT  Prophylaxis Regimen  Ce (SCD) nedications +/- compression devices: vice (SCD) - Optional mg SQ daily (WT < 150kg, CrCl > 30 mg SQ daily (WT < 150kg, CrCl > 30 mg SQ daily (WT < 150kg, CrCl > 30 mines on the back of this form) nedications PLUS compression device (SCD)  Preferred with Epidurals) red): □ 40mg SQ daily (WT < 150kg □ 30mg SQ daily (WT < 150kg, uddelines on the back of this form)	dered.  uced thrombocytopenia 3S (SGD)  considered.  mL/min) -29mL/min) nL/min)  es: , CrCl > 30mL/min) , CrCl = 10-29mL/min CrCl > 30mL/min)  Joseph A. Caprini, MD, M VTE Risk Factor Assesser	) is, FACS, Ri nent Tool

Figure 2. Risk assessment tool.

## Statistical Analysis

Patient satisfaction was assessed in 2 different ways. First, by a scripted telephone survey and second by the Press Ganey Ambulatory surgery satisfaction scores filtered for the general surgery specialty services.

The percentile ranking compares our institution to all hospitals in the Press Ganey (PG) database (1621 hospitals), our institution to the other H+H facilities (11 hospitals), and our institution to like hospitals in NY State (70 hospitals). Both DVT and VTE were assessed by using observed to

## **DVT SCRIPT**

- Hello, my name is (name, title), I would like to tell you about one of the ways we here at Jacobi keep safety for our patients as a top priority.
- Risk of blood clot forming inside a blood vessel can happen during surgery. A blood clot can be dangerous because it can travel to your lungs (called pulmonary embolism).
- The risk of this complication can be reduced and prevented with an injection just before surgery with an anticoagulant called heparin. This injection, along with special leg wraps is the best way to reduce the risk of this complication.
- We would like to do a very good job explaining this to you and keeping you informed.
- Prior to getting anesthesia for your surgery, with your permission, your physician will
  order an injection of heparin. This injection will be given by your nurse, or
  anesthesiologist subcutaneously either in the holding area or in the operating room. This
  one-time injection will help in reducing and preventing blood clots from forming.
- You might get a phone call once you are home asking you if we had a conversation with
  you about blood clots and if we gave you information on how to prevent them. We want
  to do a very good job in sharing this information and making sure you understand it.
- Do you have any questions, or can I further clarify anything about the heparin and preventing blood clots?

Figure 3. Script.

expected ratios (O:E). The VTEP initiative has since been extended to include all surgical services, including orthopedic surgery (initially with the highest VTE rate).

## **Results**

Gap analysis revealed a high degree of variability regarding VTEP on the surgical service with lack of both a standardized risk assessment tool and defined process for VTE risk assessment. Of 109 patients prior to the VTEP intervention, only 4 patients recalled having a conversation with their doctor before surgery about the following: risk of blood clots during their operation, need for VTEP, and patient safety being a top priority. The remaining 105 patients did not recall any conversation on any of these 3 topics. After implementing the VTEP project on the General Surgery Service, the observed to expected ratio (O:E) for VTE decreased from 1.92 to 1.07. The VTEP initiative has since been extended to include all surgical services, including orthopedic surgery (initially with highest VTE rate). Although O:E has not normalized, a significant reduction in VTE is shown on the general surgery service. The absolute rate decreased as the absolute number of VTE events decreased across all surgical services (Table 1, Figures 5 and 6).

Data through 1 year, November 2016 to October 2017, were studied. Of the 186 patients screened for VTEP, there was a 96% (179/186) follow-up rate in 6 months. Of the 186 patients, 89% of the patients in the study were deemed high risk. Of this group, 94 received preoperative VTEP. Telephone surveys were attempted for all 186 patients. Thirty-nine surveys were unable to be completed for the following reasons: disconnected phones, incorrect phone numbers, patient refusals to participate in the survey, and failure to return calls. Of the patients for whom the surveys were completed, 99% (145/147) of patients reported that the indications, risks, and benefits of VTEP were explained well or very well. Of these patients, 99.5% (146/147) felt that safety and well-being were a priority based on preoperative discussions. There were no incidences of VTE in this cohort. The Press Ganey Ambulatory surgery satisfaction scores filtered for the general surgery specialty services found our institution to be well above the target 50th percentile. There is no significant difference on PG results when comparing pre- and postimplementation of the VTEP program with satisfaction scores in the areas that most closely reflected perioperative performance. Press Ganey Ambulatory surgery satisfaction scores from the following 2 categories are found in Tables 2 and 3, respectively: information on the day of Castaldi et al 93




Figure 4. Clinical pathway.


**Table 1.** Observed to Expected Ratios for General Surgery Division and All Divisions.

	Observed to Expected Ratios (O:E)				
Date	General Surgery Division	All Divisions			
October 2016 July 2017	1.92 1.07	2.50 1.68			

surgery by nurse (Table 2) and explanations prior to surgery by physician (Table 3).

## **Discussion**

In this study, we assessed VTE, DVT, and patient experience after designing and implementing a QI program by analyzing O:E of VTE, patient satisfaction (telephone survey), and Press Ganey scores. We found that on the General Surgery Service O:E decreased, the absolute number of VTE events decreased, approximately 99% of high-risk patients felt that the risks and benefits were well explained and that there was no incidence of VTE in this cohort. The Press Ganey Ambulatory surgery satisfaction score found



**Figure 5.** Results, division of general surgery pre (A) and post (B) VTEP project implementation.

this institution to be well above the target of 50th percentile; however, there were no significant differences on PG results when comparing pre- and postimplementation of the VTEP program.

Team engagement is critical to success in patient engagement. It affects outcome data as well. Working as a collaborative team with surgeons, anesthesiologists, and nurses; input and ideas from all disciplines have led to improved patient outcomes and decreased incidence of VTE since program implementation. At the outset, there were several obstacles in instituting this initiative: lack of standardized VTEP protocols, lack of standard risk assessment tools, and a belief system that VTEP may cause bleeding intraoperatively. Once the initial obstacles of program implementation were overcome, a greater than 95% response rate from patients reported that safety and well-being are a priority based on preoperative discussions on VTEP. The VTE improvement soon followed in NSQIP reports.

The VTEP initiative has since been extended to include all surgical services, including orthopedic surgery (initially with the highest VTE rate). Based on our data, the Orthopedic surgery team has made modifications to VTEP dosing for their patients. Consequently, the Orthopedic service has recently begun to see improvements in their VTE O:E ratio.




Figure 6. Results, all surgical divisions.

Table 2. Press Ganey Scores Day of Surgery, Nursing.

Dates	Mean	n	All PG Database (%)	State of New York (%)	Percentile Rank to Like Hospitals in New York
July 1, 2016, to September 30, 2016	92.9	7	94.8	93.4	35
October 1, 2016, to December 31, 2016	83.3	9	95.0	93.0	I
January 1, 2017, to March 31, 2017	91.7	6	94.9	93.3	23
April 1, 2017, to June 30, 2017	93.2	П	95.0	93.6	42

The authors have recently expanded the project to include the gynecology service.

The PG results have not reflected the improved immediate survey results for several reasons. Different aspects of patient care determine patient experience. The ability of clinicians to empathize, respect the preferences of patients, and include them in decision-making are much harder to quantify than functional aspects of care such as timeliness of care, clean and safe environments, and effective coordination of services. However, both aspects of care are

**Table 3.** Press Ganey Scores, Explanations prior to Surgery, Physician.

Dates	Mean	n	All PG Database (%)	State of New York (%)	Percentile Rank to Like Hospitals in New York
July 1, 2016, to September 30, 2016	92.9	7	94.8	93.8	32
October 1, 2016, to December 31, 2016	86.1	9	94.4	93.5	2
January 1, 2017, to March 31, 2017	96.4	7	94.5	93.8	90
April 1, 2017, to June 30, 2017	93.2	П	94.4	93.5	47

incorporated into PG data. Telephone survey targeting the conversation regarding VTEP shows an improvement that relates specifically to patient-centered discussions on VTEP.

Although scripted dialogue was prepared, measures used to capture patient satisfaction still reflect interpersonal care experiences, such as patient–provider communication, which represent a unique dimension of quality. A telephone survey done within 3 to 5 days of hospitalization does align with prior studies that show positive associations with outcome measures (10–12). One drawback is the average lag between measured experience feedback and outcome of 3.9 years (13). In addition, the PG questions are much vaguer and may reflect or are biased by total day of surgery experience.

Numerous studies have demonstrated significant positive relationships between patients' perceptions of their care experiences and outcomes (14). Patient experience is positively associated with clinical effectiveness and patient safety and supports the inclusion of patient experience in quality initiatives (15) In addition, measures of health-care quality such as compliance with recommended treatment, better clinical outcomes, improved patient safety, and more efficient health care utilization correlate positively with patient satisfaction (16). Our findings offer further support for these studies. As we found, VTEP patient-centered discussion and shared-discussion did affect patients' perceptions of their care and their outcomes.

There are limitations to such a study. The actual quality of the individual interactions is difficult to quantify and may vary significantly from provider to provider. Indeed, interaction may vary from day to day with an individual provider. Further, the actual understanding of the medical information by the patient cannot be quantified. However, the Ask-Tell-Ask paradigm (17) was developed for collaborative communication which included assessing the patient's existing knowledge on VTE and VTEP before sharing information on VTEP, as patients were not asked to reiterate the risk and benefits of VTEP. The level of understanding and correlation with outcomes is similarly

Castaldi et al 95

not quantifiable. While the authors are satisfied with the integrity of the NSQIP data in showing overall institutional improvement, the authors acknowledge that NSQIP is sampling methodology and not all cases may have been captured. Moving forward, the authors seek to develop a randomized multi-institutional study.

### Conclusion

Using NSQIP data and a program developed for both VTE risk assessment and patient experience, the authors observe immediate improvements in patient satisfaction and no VTE. Although there are unresolved methodology related to the measurement and interpretation of patient experiences regarding survey content, and timing of survey administration, we believe quality care and patient engagement can improve the patient experience and outcomes. Patient-centered discussions have had positive impact on patient's perioperative experience regarding VTEP and safety as a top priority.

## **Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## **Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## References

- https://www.cdc.gov/ncbddd/dvt/data.html. Accessed September 27, 2018.
- Heit JA, Melton LJ III, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 2001;76:1102-10.
- Guyatt GH, Eikelboom JW, Gould MK, et al. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e185S-94S.
- Kahn SR, Morrison DR, Diendéré G, et al. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism. Cochrane Database Syst Rev. 2018;4:CD008201. doi: 10.1002/14651858.CD008201.pub3.
- Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasoundconfirmed deep vein thrombosis. Am J Cardiol. 2004;93: 259-62. pmid:14715365
- Cohen AT, Tapson VF, Bergmann J, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387-94.
- 7. www.facs.org/quality-programs/acs-nsqip. 2004. Accessed on September 24, 2018.
- 8. Xu Y, Zhao J, Chen Y. Prevention of venous thromboembolism in patients undergoing major orthopedic surgery in china: a

- qualitative study of patients' perceptions. J Orthop Surg Res. 2018;13:98-018-0813-2.
- Bahl V, Hu H, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010;251:344-50.
- Jha AK, Orav EJ, Zheng J, Epstein AM. Patients' perception of hospital care in the United States. N Engl J Med. 2008;359: 1921-31.
- Boulding W, Glickman SW, Manary MP, Schulman KA, Staelin R. Relationship between patient satisfaction with inpatient care and hospital readmission within 30 days. Am J Manag Care. 2011;17:41-8.
- Glickman SW, Boulding W, Manary M, et al. Patient satisfaction and its relationship with clinical quality and inpatient mortality in acute myocardial infarction. Cir Cardiovasc Qual Outcomes. 2010;3:188-95.
- 13. Fenton JJ, Jerant AF, Bertakis KD, Franks P. The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch Intern Med. 2012;172:405-11. doi:10.1056/NEJMp1211775.
- 14. Kennedy GD, Tevis SE, Kent KC. Is there a relationship between patient satisfaction and favorable outcomes? Ann Surg. 2014;260:592-8.
- Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Nov. 2012. doi:10.1136/bmjopen-2012-001570.
- Anhang PR, Elliott MN, Zaslavsky AM, et al. Examining the role of patient experience surveys in measuring health care quality. Med Care Res Rev. 2014;71:522-54.
- 17. Kemp EC, Floyd MR, McCord-Duncan E, Lang F. Patients prefer the method of "tell back-collaborative inquiry" to assess understanding of medical information. J Am Board Fam Med. 2008;21:24-30.

## **Author Biographies**

Maria Castaldi, MD FACS, is the Director of Surgical Quality, Jacobi Medical Center, Bronx , NY. She is Chairperson for the Doctor's Council Facility-based Collaboration Council on Quality. She is Associate Professor of Surgery at the Albert Einstein College of Medicine, Bronx NY 11030. Dr. Castaldi is currently Chief of Breast Surgery for the Westchester Medical Center Health Network, Valhalla, New York.

**Geena George**, MPH, is currently a research coordinator with the Department of Surgery's Clincial Research Unit for the Westchester Medical Center Health Network, Valhalla, New York.

**Pamela Turner**, MSN, RN, is the Network Director of Nursing for Perioperative Services and Interventional Radiology at Jacobi Medical Center & North Central Bronx Hospital, Bronx NY.

**John McNelis**, MD, FACS, FCCM, is the Chairman, Department of Surgery at Jacobi Medical Center and North Central Bronx Hospital, Bronx, NY. He is the surgeon champion for NSQIP at Jacobi Medical Center. He is Professor of Surgery at the Albert Einstein College of Medicine, Bronx NY 11030.